Systematic review and meta-analysis of the association between cytochrome P450 2C19 genotype and bleeding

被引：18
作者：
Sorich, Michael J. [1 ]
Polasek, Thomas M. [2 ]
Wiese, Michael D. [1 ]
机构：
[1] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia
[2] Flinders Univ S Australia, Sch Med, Dept Clin Pharmacol, Adelaide, SA 5001, Australia
来源：
THROMBOSIS AND HAEMOSTASIS | 2012年 / 108卷 / 01期
关键词：
PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; CYP2C19; GENOTYPE; STENT THROMBOSIS; CLOPIDOGREL; POLYMORPHISMS; EVENTS; OUTCOMES; PRASUGREL; TRIAL;
D O I：
10.1160/TH12-02-0095
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：199 / 200
页数：2
相关论文
共 15 条
  • [1] [Anonymous], REV MAN REVMAN VERS
  • [2] Bhatt DL, 2012, CHARISMA GENOMICS SU
  • [3] Meta-analysis of the efficacy and safety of clopidogrel plus aspirin as compared to antiplatelet monotherapy for the prevention of vascular events
    Bowry, Ashna D. K.
    Brookhart, M. Alan
    Choudhry, Niteesh K.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (07) : 960 - 966
  • [4] Prospective Evaluation of On-Clopidogrel Platelet Reactivity Over Time in Patients Treated With Percutaneous Coronary Intervention Relationship With Gene Polymorphisms and Clinical Outcome
    Campo, Gianluca
    Parrinello, Giovanni
    Ferraresi, Paolo
    Lunghi, Barbara
    Tebaldi, Matteo
    Miccoli, Matteo
    Marchesini, Jlenia
    Bernardi, Francesco
    Ferrari, Roberto
    Valgimigli, Marco
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2011, 57 (25) : 2474 - 2483
  • [5] The influence of CYP2C19*2 and*17 on on-treatment platelet reactivity and bleeding events in patients undergoing elective coronary stenting
    Harmsze, Ankie M.
    van Werkum, Jochem W.
    Hackeng, Christian M.
    Ruven, Hendrik J. T.
    Kelder, Johannes C.
    Bouman, Heleen J.
    Breet, Nicoline J.
    ten Berg, Jurrien M.
    Klungel, Olaf H.
    de Boer, Anthonius
    Deneer, Vera H. M.
    [J]. PHARMACOGENETICS AND GENOMICS, 2012, 22 (03) : 169 - 175
  • [6] The Importance of High-Quality Evidence of the Long-Term Impact of Nonfatal Events Used in Randomized Controlled Trials: A Case Study of Prasugrel
    Lu, C. Y.
    Karnon, J.
    Sorich, M. J.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2011, 90 (01) : 27 - 29
  • [7] Relationship between Cytochrome P450 2C19*2 Polymorphism and Stent Thrombosis following Percutaneous Coronary Intervention in Chinese Patients Receiving Clopidogrel
    Luo, Y.
    Zhao, Y-T
    Verdo, A.
    Qi, W-G
    Zhang, D-F
    Hu, B.
    [J]. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 2011, 39 (05) : 2012 - 2019
  • [8] Cytochrome P-450 Polymorphisms and Response to Clopidogrel.
    Mega, Jessica L.
    Close, Sandra L.
    Wiviott, Stephen D.
    Shen, Lei
    Hockett, Richard D.
    Brandt, John T.
    Walker, Joseph R.
    Antman, Elliott M.
    Macias, William
    Braunwald, Eugene
    Sabatine, Marc S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (04) : 354 - 362
  • [9] Effects of CYP2C19 Genotype on Outcomes of Clopidogrel Treatment
    Pare, Guillaume
    Mehta, Shamir R.
    Yusuf, Salim
    Anand, Sonia S.
    Connolly, Stuart J.
    Hirsh, Jack
    Simonsen, Katy
    Bhatt, Deepak L.
    Fox, Keith A. A.
    Eikelboom, John W.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (18) : 1704 - 1714
  • [10] Metabolic activation of clopidogrel: in vitro data provide conflicting evidence for the contributions of CYP2C19 and PON1
    Polasek, Thomas M.
    Doogue, Matthew P.
    Miners, John O.
    [J]. THERAPEUTIC ADVANCES IN DRUG SAFETY, 2011, 2 (06) : 253 - 261
12